Risk factors: Persistent aPL antibodies do not affect pregnancy outcomes

  • Published 2013 in Nature Reviews Rheumatology

Abstract

A 2-year trial has validated a methotrexate-first strategy for early poor-prognosis rheumatoid arthritis. The study outcomes indicate that around 30% of patients starting on methotrexate monotherapy will achieve low disease activity without progression to combination therapy; for the 70% that do require step-up to combination approaches, clinical and radiographic outcomes are near identical to those of patients initially treated with methotrexate combined with either etanercept or sulfasalazine and hydroxycholoquine.

DOI: 10.1038/nrrheum.2013.87

Cite this paper

@article{2013RiskFP, title={Risk factors: Persistent aPL antibodies do not affect pregnancy outcomes}, author={}, journal={Nature Reviews Rheumatology}, year={2013}, volume={9}, pages={382-382} }